NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
January 18, 2022 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
January 05, 2022 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
December 12, 2021 15:40 ET
|
NexImmune, Inc.
Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionPhase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory...
NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 12, 2021 07:30 ET
|
NexImmune, Inc.
Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022Announced collaboration with Yale University...
NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021
November 08, 2021 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting
November 03, 2021 08:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 27, 2021 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 10, 2021 09:11 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 09, 2021 16:05 ET
|
NexImmune, Inc.
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated...
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
August 09, 2021 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...